Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Editorials
You have accessRestricted Access

Sequestration and Suppression of Anti-HLA Antibodies by a Failed Kidney Allograft

Vinay Nair and Peter S. Heeger
CJASN August 2012, 7 (8) 1209-1210; DOI: https://doi.org/10.2215/CJN.06230612
Vinay Nair
Division of Nephrology, Department of Medicine and the Recanati-Miller Transplant Institute, Mount Sinai School of Medicine, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter S. Heeger
Division of Nephrology, Department of Medicine and the Recanati-Miller Transplant Institute, Mount Sinai School of Medicine, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • View PDF
Loading

Nephrectomy of a failed kidney transplant is indicated for hematuria and local pain (usually attributed to rejection), but may be done electively to facilitate cessation of immunosuppression. Transplant nephrectomy may also limit long-term cardiovascular risk (1). Despite these potential benefits, transplant nephrectomy can be complicated by morbidities surrounding surgery, and several retrospective reports suggest that nephrectomy is associated with an increase in circulating anti-HLA antibodies (1–6). The enduring implications of the latter are significant because anti-HLA antibodies confer both an increase wait time for retransplantation and elevated risk for subsequent graft failure (7,8).

The pathogenesis of the reported increase in anti-HLA antibodies remains unclear. Tapering immunosuppression before or after nephrectomy may unleash restrained T and B cell alloreactivity directed at the remaining viable donor tissue (even after nephrectomy, residual donor ureteral tissue commonly remains), leading to new alloantibody production. Alternatively or in addition, donor-reactive memory B cells or plasma cells may be chronically producing antibodies, but while the transplanted organ is in place, these anti-HLA antibodies are absorbed by the graft. Following nephrectomy, antibody production may not change, but because removal of the graft eliminates the “antigen sink,” levels of circulating anti-HLA antibodies rise (9). Systematically delineating the effects of transplant nephrectomy on circulating anti-HLA antibodies and clarifying mechanisms are important because the conclusions can impact clinical decision-making. The paper by Del Bello et al. (10) in this issue of CJASN sheds new light on these issues.

In the study of Del Bello et al., the authors compared two groups of kidney transplant recipients with failed allografts: 21 patients who had their immunosuppression tapered with the graft in place and 48 who had a graft nephrectomy either for graft intolerance or as part of the center’s standard protocol. The investigators used Luminex single antigen beads, the most sensitive assay for detecting anti-HLA antibody, to quantify the kinetics, frequency, and antigen specificity of anti-HLA antibodies. They examined serum from each patient at the time of graft failure, at a time point immediately after tapering immunosuppression, and serially after nephrectomy. While the investigators detected donor specific anti-HLA antibodies (DSAs) in a low percentage of patients at the time of graft failure (12%–14%), the kinetic studies revealed the prevalence of serum DSAs increased to 35.4% after cessation of immunosuppressive therapy but prior to nephrectomy. Sixty-six percent of those who underwent nephrectomy had detectable circulating DSAs within 5 days, and this increased to 81.4% at 3 months and 84.6% at 9 months. The prevalence of serum DSAs also increased in those without nephrectomy (52.4%) but was significantly lower than those who underwent nephrectomy. There was no difference in DSAs between patients who underwent allograft nephrectomy for an indication (e.g., local pain) compared with those who had a scheduled removal of the failed graft. The predominant DSA that appeared after nephrectomy was reactive to class I HLA molecules, found in 23% in patients without nephrectomy versus 77% of patients with nephrectomy. Although the strength of the antibody as measured by mean fluorescent intensity (MFI) can only be estimated using Luminex technology, the authors did not note a significant change in the strength of the alloantibodies over the course of the study in either group. Interestingly, the emergence of anti-HLA antibodies reactive to other HLA alleles (non-DSAs) was numerically higher in patients who had a graft nephrectomy (85% versus 67%), but this did not reach statistical significance. Although no patients died, nephrectomy was associated with a 30% complication rate.

What makes this report unique is that all study subjects had their immunosuppression stopped prior to intervention, whereas other studies have either not clarified this point or stopped immunosuppression after nephrectomy (2–4). Del Bello and colleagues clearly documented an elevation in anti-HLA antibodies after stopping immunosuppression and then showed that those with a graft nephrectomy had an even further rise. Limitations of the study include the relatively small number of patients and lack of knowledge regarding the strength of the de novo DSAs. Although the authors did not report a change in MFI and included any antibody with an MFI >500, the current literature suggests that the risk of antibody-mediated rejection is directly correlated with the strength of MFI of the DSAs (11,12).

In terms of mechanisms, based on their kinetic data, the authors favor the hypothesis the transplant itself is the sensitizing event, and HLA antibodies are likely present long before nephrectomy but are absorbed by the graft (9,13). Others have indeed shown that donor-reactive anti-HLA antibodies can be eluted from nephrectomized allograft specimens (13), supporting this possibility. Because cessation of immunosuppression without nephrectomy was associated with an increase in serum DSAs in the study of Del Bello et al., it is also possible that de novo alloantibodies were induced after immunosuppression was stopped. One potential approach for further dissecting mechanisms would be to quantify donor HLA-reactive B cells (14) and plasma cells (15) in the recipient and correlate the findings with circulating antibodies. If one detected high frequencies of donor-reactive B cells/plasma cells without circulating antibodies in patients with failed transplants and this frequency did not change after nephrectomy (but circulating antibodies increased), the results would support the theory that the graft is absorbing antibodies induced by the transplant.

Regardless of specific mechanisms, the data from Del Bello et al. add to the literature by documenting that circulating anti-HLA antibody should be expected to rise after nephrectomy. How this finding should impact clinical care remains unanswered. Retrospective analyses clouded by significant bias (1,5,16–18) have not yet provided clear directives regarding effects of nephrectomy (and circulating anti-HLA antibodies) on graft outcomes following retransplantation. If the patient is not a retransplant candidate and can tolerate surgery, or if a patient has a clear indication for graft removal (e.g., hematuria, graft pain, signs of chronic inflammation), the benefits of nephrectomy likely outweigh the risks. If the patient is an asymptomatic retransplant candidate, one option would be to keep the graft in place to sequester any anti-HLA antibodies, potentially avoiding the difficulties in finding a suitable donor for a sensitized individual and lowering the risk of injury to a new graft. This approach needs to be balanced against the probable cardiovascular risks and the known complications of prolonged low-dose immunosuppression. Although the study by Del Bello et al. adds evidence to a growing body of literature that graft nephrectomy leads to an elevation in circulating HLA antibody, prospective studies in which patients are randomized to nephrectomy plus retransplant or retransplant without nephrectomy, using graft survival, patient mortality, and retransplant rates as end points, are still required.

Disclosures

None.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • See related article, “Donor-Specific Antibodies after Ceasing Immunosuppressive Therapy, with or without an Allograft Nephrectomy,” on pages 1310–1319.

  • Copyright © 2012 by the American Society of Nephrology

References

  1. 1.↵
    1. Ayus JC,
    2. Achinger SG,
    3. Lee S,
    4. Sayegh MH,
    5. Go AS
    : Transplant nephrectomy improves survival following a failed renal allograft. J Am Soc Nephrol 21: 374–380, 2010
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Khakhar AK,
    2. Shahinian VB,
    3. House AA,
    4. Muirhead N,
    5. Hollomby DJ,
    6. Leckie SH,
    7. McAlister VC,
    8. Chin JL,
    9. Jevnikar AM,
    10. Luke PP
    : The impact of allograft nephrectomy on percent panel reactive antibody and clinical outcome. Transplant Proc 35: 862–863, 2003
    OpenUrlCrossRefPubMed
  3. 3.
    1. Marrari M,
    2. Duquesnoy RJ
    : Detection of donor-specific HLA antibodies before and after removal of a rejected kidney transplant. Transpl Immunol 22: 105–109, 2010
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Billen EV,
    2. Christiaans MH,
    3. Lee J,
    4. van den Berg-Loonen EM
    : Donor-directed HLA antibodies before and after transplantectomy detected by the luminex single antigen assay. Transplantation 87: 563–569, 2009
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Johnston O,
    2. Rose C,
    3. Landsberg D,
    4. Gourlay WA,
    5. Gill JS
    : Nephrectomy after transplant failure: Current practice and outcomes. Am J Transplant 7: 1961–1967, 2007
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Secin FP,
    2. Rovegno AR,
    3. del Rosario Brunet M,
    4. Marrugat RE,
    5. Dávalos Michel M,
    6. Fernandez H
    : Cumulative incidence, indications, morbidity and mortality of transplant nephrectomy and the most appropriate time for graft removal: Only nonfunctioning transplants that cause intractable complications should be excised. J Urol 169: 1242–1246, 2003
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Opelz G
    ; Collaborative Transplant Study: Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 365: 1570–1576, 2005
    OpenUrlCrossRefPubMed
  8. 8.↵
    Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR): OPTN / SRTR 2010 Annual Data Report. Available at http://www.srtr.org/annual_reports/2010/502_pra_ki.htm. Accessed June 10, 2012.
  9. 9.↵
    1. Lenaers J,
    2. Christiaans M,
    3. van Heurn E,
    4. van Hooff H,
    5. van den Berg-Loonen E
    : Frequent but late donor-directed antibody formation after kidney transplantectomy within one month after grafting. Transplantation 81: 614–619, 2006
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Del Bello A,
    2. Congy-Jolivet N,
    3. Sallusto F,
    4. Guilbeau-Frugier C,
    5. Cardeau-Desangles I,
    6. Marylise Fort,
    7. Esposito L,
    8. Guitard J,
    9. Cointault O,
    10. Lavayssiere L,
    11. Nogier MB,
    12. Blancher A,
    13. Rostaing L,
    14. Lamar N
    : Donor-specific antibodies after ceasing immunosuppressive therapy, with or without an allograft nephrectomy. Clin J Am Soc Nephrol 7: 1310–1319, 2012
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Akalin E,
    2. Dinavahi R,
    3. Friedlander R,
    4. Ames S,
    5. de Boccardo G,
    6. Sehgal V,
    7. Schröppel B,
    8. Bhaskaran M,
    9. Lerner S,
    10. Fotino M,
    11. Murphy B,
    12. Bromberg JS
    : Addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies. Clin J Am Soc Nephrol 3: 1160–1167, 2008
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Lefaucheur C,
    2. Suberbielle-Boissel C,
    3. Hill GS,
    4. Nochy D,
    5. Andrade J,
    6. Antoine C,
    7. Gautreau C,
    8. Charron D,
    9. Glotz D
    : Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant 8: 324–331, 2008
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Heinemann FM,
    2. Roth I,
    3. Rebmann V,
    4. Arnold ML,
    5. Spriewald BM,
    6. Grosse-Wilde H
    : Characterization of anti-HLA antibodies eluted from explanted renal allografts. Clin Transpl 2006: 371–378, 2006
  14. 14.↵
    1. Zachary AA,
    2. Kopchaliiska D,
    3. Montgomery RA,
    4. Leffell MS
    : HLA-specific B cells: I. A method for their detection, quantification, and isolation using HLA tetramers. Transplantation 83: 982–988, 2007
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Diwan TS,
    2. Raghavaiah S,
    3. Burns JM,
    4. Kremers WK,
    5. Gloor JM,
    6. Stegall MD
    : The impact of proteasome inhibition on alloantibody-producing plasma cells in vivo. Transplantation 91: 536–541, 2011
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Ahmad N,
    2. Ahmed K,
    3. Mamode N
    : Does nephrectomy of failed allograft influence graft survival after re-transplantation? Nephrol Dial Transplant 24: 639–642, 2009
    OpenUrlCrossRefPubMed
  17. 17.
    1. Schleicher C,
    2. Wolters H,
    3. Kebschull L,
    4. Anthoni C,
    5. Suwelack B,
    6. Senninger N,
    7. Palmes D
    : Impact of failed allograft nephrectomy on initial function and graft survival after kidney retransplantation. Transpl Int 24: 284–291, 2011
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Lair D,
    2. Coupel S,
    3. Giral M,
    4. Hourmant M,
    5. Karam G,
    6. Usal C,
    7. Bignon JD,
    8. Brouard S,
    9. Soulillou JP
    : The effect of a first kidney transplant on a subsequent transplant outcome: An experimental and clinical study. Kidney Int 67: 2368–2375, 2005
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 7 (8)
Clinical Journal of the American Society of Nephrology
Vol. 7, Issue 8
August 07, 2012
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Sequestration and Suppression of Anti-HLA Antibodies by a Failed Kidney Allograft
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Sequestration and Suppression of Anti-HLA Antibodies by a Failed Kidney Allograft
Vinay Nair, Peter S. Heeger
CJASN Aug 2012, 7 (8) 1209-1210; DOI: 10.2215/CJN.06230612

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Sequestration and Suppression of Anti-HLA Antibodies by a Failed Kidney Allograft
Vinay Nair, Peter S. Heeger
CJASN Aug 2012, 7 (8) 1209-1210; DOI: 10.2215/CJN.06230612
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Footnotes
    • References
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Telehealth and Kidney Disease Care
  • Time to Abandon Kidney Biopsy to Diagnose Membranous Nephropathy?
  • Should We Let Dialysis Patients Eat Their Fruits and Veggies?
Show more Editorials

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • Donor-Specific Antibodies after Ceasing Immunosuppressive Therapy, with or without an Allograft Nephrectomy
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals
  • Wolters Kluwer Partnership

© 2022 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire